We’re on a mission!
MY01 Inc. is on a mission to empower healthcare professionals with the ability to pre-empt severe medical conditions thereby improving patient outcomes.
We believe that adding actionable quantitative data at the bedside during these interactions is the best way to make a meaningful impact to the patient while improving the experience of providing care. MY01 Inc. focuses on delivering actionable data at the bedside to augment clinical assessments. Qualitative People to People Assessments are at the core of personalized healthcare.
Nationalities in Our Team
Physician-Patient engagement is key to effective healthcare.
Healthcare is human.
Edward Harvey, MDCM
Chief Medical Officer
Charles Allan, M.Eng
Chief Executive Officer
George Xereas, PhD
Chief Technology Officer
Dr. Edward J. Harvey has a rich history of collaboration with basic, clinical and engineering scientists. He is a tenured Professor of Surgery at McGill University. He is the trauma research program leader at the Research Institute of the McGill University Health Centre (RI-MUHC) with over 60 investigators in his group. He is, or has been, editor-in-chief of the Canadian Journal of Surgery; editorial board member of the Journal of Orthopaedic Trauma and OTA International; chairman of the Research Committee and the Annual meeting program chair for the Orthopedic Trauma Association; chair of the Trauma Section at the Orthopaedic Research Society; and president of the Canadian Orthopaedic Association amongst other national and international positions.
Charles is passionate about using really small things to solve big problems. Being surrounded by many successful and supportive entrepreneurs, he quickly gained an ability to create teams and transform problems into solutions.
An example of his passion at work can be found during his undergraduate years at Queens University, where he helped build a microfluidic pump for an implantable therapeutic for glaucoma. This project helped ignite his entrepreneurial spirit, and, while pursuing his Masters in Bioelectrical Engineering at McGill University, he formed a team that combined engineering and technology to develop microsolutions. Some of those initial microsystems are the foundational components used by the three companies that Charles founded: MY01, Inc., Stathera, Inc., and NXTSENS Microsystems, Inc. These companies each have won several awards and been selected for important growth accelerators. They have grown to over 70 employees, and combined to raise over $50M in funding.
George Xereas is the Chief Technology Officer at MY01 Inc. In this role, he leads the company’s technology and product development. Prior to MY01 Inc., he served as the Chief Technology Officer for NXTSENS Microsystems Inc., a fabless MEMS based sensor company he co-founded. George obtained his PhD in Electrical and Electronics Engineering from McGill University in 2017, which was supported by the Les Vadasz Doctoral Fellowship in Engineering – Intel. George is an author in 19 high impact publications in MEMS sensors, and is an inventor in 14 utility patents.
We started as a Master’s project at McGill University. Founders, Dr. Ed Harvey, Charles Allan and George Xereas, worked on developing a MEMS-based pressure sensor that acts as a reliable ACS diagnostic tool. As we continued development we realized that we could apply our knowledge to broader applications, tackling other healthcare challenges.
What started off as a Master’s project at McGill University becomes an official startup as our founders: Charles, Ed and George, officially register the project as a corporate entity.
Spring & Summer, 2016
Nxtsens Takes the Cup: Dobson Cup & X-1
Nxtsens, our parent company, was awarded second place in the health science track at the McGill flagship startup competition, the McGill Dobson Cup. We followed this achievement with our participation in the X-1 program, a Montreal-based accelerator, during the summer of 2016.
MY01 Cracks the Top 50 at MedTech
We are selected out of 600 applicants to pitch at the MedTech Innovator Showcase, a medical technology industry’s global showcase and accelerator. Our participation leads us to rank amongst the Top 50 in the showcase.
Moving Day: MY01 moves to 85 Rue St. Paul West
As the company continues to rapidly expand, we outgrown our previous co-working space. Our team moves into an exciting, new, dedicated office space in the old port of Montreal.
MY01 in the Top 20 of the MedTech Innovator Accelerator
We are selected as a part of the top 20 amongst 700 applicants worldwide of the MedTech Innovator, a global competition and accelerator for medical devices, digital health and diagnostic companies.
MY01 Wins at the Medtech Conference in Philadelphia
Simon and Charles travel to Philadelphia to introduce MY01 to potential partner companies and investors at the Medtech Conference in Philadelphia where we win an award for “Best Video”.
We were awarded a prize for exemplary integration of its immigrant workforce
At MY01, we are extremely proud of our diversity, most of our employees are first generation immigrants. With many expressing interest in joining the Ordre des Ingénieurs du Québec, we started offering French in the office with French proficiency being a requirement to join the OIQ. We were recognized as an exemplary employer for integration of its immigrant workforce by the Office Québecois de la Langue Française.
MY01 passes ISO 13485 :2016 Audit
MY01’s Quality Management System (QMS) has been deemed compliant with the International Standard ISO 13485 “Medical devices — Quality Management Systems”
MY01 Receives CE Mark
MY01 has received positive notice from the European Commission for our MY01 Compartmental Pressure Monitor Device. We can now begin selling our device across the European Union.
MY01 receives MDSAP
MY01 has received its Medical Device Single Audit Program Certificate. The document certifies the compliance of our Quality Management System and allows us to apply for regulatory approvals in the US and in Canada.
MY01 Receives Health Canada Medical Device Licence
MY01 has received positive notice from Health Canada for our MY01 Compartmental Pressure Monitor Device. We can now begin selling our device across Canada.
MY01 receives 510k Clearance
MY01 has received its 510k clearance from the Food & Drug Administration (FDA) for its MY01 Compartmental Pressure Monitor.
MY01 moves into its new office
As the company has been growing at an impressive rate we had outgrown our old offices and had to size up with brand new offices in the heart of downtown Montreal at 400 Boul de Maisonneuve West, Suite 700.
MY01 launches its online learning center
MY01 Inc. has launched its online learning platform focused on keeping various stakeholders up to speed on current literature related to compartment syndrome, our most recent peer reviewed publications, and documentation related to our value proposition. Click here to visit
The MY01 Mobile Application receives FDA 510k clearance
MY01 has received a 510k clearance for the companion MY01 Mobile Application.
MY01 granted Breakthrough Device Designation
MY01 Inc. has received its first-ever “Breakthrough Device” designation by the FDA in October, joining a select list of Orthopaedic companies to receive this designation since the program began in 2016.